Tüdőrák: vizsgálatok itt: Kína

In Kína 1144 Also abroad 2746

1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Where
Shanghai, Zhengzhou
Életkor
18 év and over
People
562
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07502300
2. fázisFut, nem toboroz
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
Életkor
18 év and over
People
128 worldwide
Run by
Teligene US
See details and how to joinNCT05168566
1/2. fázisTaking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Beijing, Changsha, Chengdu, Fuzhou, Kunming, Liuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou
Életkor
18 év and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
3. fázisTaking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou Fujian, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nanyang, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
Életkor
18 év and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
2. fázisTaking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Beijing, Chengdu, Nanchang, Shanghai, Wuhan, Zhengzhou
Életkor
18 év and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
2. fázisTaking people
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Where
Beijing
Életkor
18 év and over
People
60
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07622706
No phaseNot yet taking people in Kína
Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
Where
Wuhan
Életkor
18 év and over
People
3000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07882758
3. fázisNot yet taking people in Kína
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Where
Shanghai
Életkor
18 év and over
People
425
Run by
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
See details and how to joinNCT07897188
2. fázisTaking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Chengdu, Guangzhou
Életkor
18 év and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Korai 1. fázisTaking people
mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors
Where
Beijing
Életkor
Up to 99 év
People
83
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06928922
2. fázisTaking people
D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Where
Guangzhou
Életkor
18 év to 75 év
People
46
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07016126
Korai 1. fázisTaking people
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
Where
Nanjing
Életkor
18 év to 75 év
People
24
Run by
TCRCure Biopharma Ltd.
See details and how to joinNCT07246304
No phaseTaking people
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Where
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou, Handan, Hefei, Huzhou, Jinan, Jining, Linhai, Linyi, Lishui, Liuzhou, Nanchang, Nanjing, Nanning, Nantong, Qiqihar, Shanghai, Shaoxing, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Suining, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xiangyang, Yangzhou, Zhoushan, Zunyi
Életkor
18 év and over
People
1000
Run by
AstraZeneca
See details and how to joinNCT07613424
No phaseTaking people
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Where
Shanghai
Életkor
18 év to 90 év
People
294
Run by
Shanghai Chest Hospital
See details and how to joinNCT07681245
No phaseTaking people
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Where
Beijing
Életkor
18 év to 85 év
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07894458
No phaseTaking people
Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
Where
Wuhan
Életkor
35 év and over
People
6000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07895277
3. fázisNot yet taking people in Kína
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
Where
Hangzhou, Shanghai
Életkor
18 év to 75 év
People
436
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07896005
No phaseTaking people
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Where
Beijing
Életkor
18 év to 80 év
People
470
Run by
Sun Yat-sen University
See details and how to joinNCT06644430
3. fázisTaking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Hong Kong, Jinan, Jordan, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
Életkor
18 év and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
1/2. fázisTaking people
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Shengyang, Taizhou, Tianjin
Életkor
18 év and over
People
220
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07079475
3. fázisTaking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shanghai Shi, Shantou, Shenyang, Wuhan, Xiamen, Xi'an, Xiangyang, Zhangzhou, Zhengzhou
Életkor
18 év and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
2. fázisTaking people
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Where
Guangzhou
Életkor
18 év to 75 év
People
61
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07416058
2. fázisTaking people
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
Where
Guangzhou
Életkor
18 év to 80 év
People
32
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07472478
2. fázisNot yet taking people in Kína
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Beijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai, Wuhan
Életkor
18 év and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
2. fázisTaking people
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Where
Wuhan
Életkor
18 év and over
People
76
Run by
Hansoh BioMedical R&D Company
See details and how to joinNCT07824882